Abiraterone acetate exerts a cytotoxic effect in human prostate cancer cell lines

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Prostate cancer (PCa) often relies on androgen receptor (AR) signaling.
• Abiraterone acetate (AER) is a CYP17A1 inhibitor used in PCa treatment.
• Understanding AER's mechanism against AR activation is crucial for optimizing therapy.

Purpose of the Study:

• To investigate abiraterone acetate's (AER) capability to antagonize androgen receptor (AR) activation in human prostate cancer (PCa) cell lines.
• To explore the cytotoxic mechanisms of AER and its metabolite Δ4A in PCa.
• To assess AER's efficacy against AR mutations, specifically T877A-AR.

Main Methods:

• Cell viability assays (MTT, cell count) on various PCa cell lines (LNCaP, VCaP, DU145, PC3).
• Gene-silencing experiments to confirm AR's role.
• In silico molecular docking to study AER and enzalutamide (ENZ) interaction with T877A-AR.
• High-performance liquid chromatography (HPLC) to quantify Δ4A production.

Main Results:

• AER demonstrated cytotoxicity across PCa cell lines, primarily through apoptosis induction.
• AER bound to AR similarly to dihydrotestosterone (DHT), with higher binding energy for T877A-AR.
• LNCaP cells' ability to synthesize the metabolite Δ4A may contribute to AER's cytotoxic effect.
• AER modulated AR target gene expression, indicating direct AR activity interference.

Conclusions:

• AER-induced cytotoxicity in PCa cells is mediated by AR binding.
• The high affinity of AER for T877A-AR suggests potential utility in managing CRPC with this mutation.
• Resistance to AER in T877A-AR expressing CRPC may be linked to increased progesterone levels.